Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma

PURPOSE: Anti-PD-1 therapy provides clinical benefit in 40–50% of patients with relapsed and/or metastatic head and neck squamous cell carcinoma (RM-HNSCC). Selection of anti- PD-1 therapy is typically based on patient PD-L1 immunohistochemistry (IHC) which has low specificity for predicting disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Flanagan, Kevin C., Earls, Jon, Schillebeeckx, Ian, Hiken, Jeffrey, Wellinghoff, Rachel L., LaFranzo, Natalie A., Bradley, Zachary S., Babbitt, Joey, Westra, William H., Hsu, Raymond, Nadauld, Lincoln, Mcleod, Howard, Firth, Sean D., Sharp, Brittany, Fuller, Josh, Vavinskaya, Vera, Sutton, Leisa, Deichaite, Ida, Bailey, Samuel D., Sandulache, Vlad C., Rendo, Matthew J., Macdonald, Orlan K., Welaya, Karim, Wade, James L., Pippas, Andrew W., Slim, Jennifer, Bank, Bruce, Saccaro, Steven J., Sui, Xingwei, Akhtar, Adil, Balaraman, Savitha, Kossman, Steven E., Sonnier, Scott A., Shenkenberg, Todd D., Alexander, Warren L., Price, Katherine A., Bane, Charles L., Ley, Jessica, Messina, David N., Glasscock, Jarret I., Cohen, Ezra E. W., Adkins, Douglas R., Duncavage, Eric J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590294/
https://www.ncbi.nlm.nih.gov/pubmed/37552307
http://dx.doi.org/10.1007/s00432-023-05205-z

Ejemplares similares

Ejemplares similares